Form 4: Tarsus Pharmaceuticals COO Seshadri Neervannan Sells Shares to Cover Tax Obligations

Seshadri Neervannan, COO of Tarsus Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.

Summary

• On March 18, 2025, Seshadri Neervannan, the Chief Operating Officer of Tarsus Pharmaceuticals, sold 2,605 shares of common stock at a price of $46.29.
• On March 19, 2025, Neervannan sold 2,543 shares of common stock at a price of $47.4.
• On March 20, 2025, Neervannan sold 2,435 shares of common stock at a price of $50.11.
• These sales were to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units and were not discretionary transactions.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is related to tax obligations and doesn't necessarily reflect the officer's view on the company's performance.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by a company officer could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the stated reason for the sale.

Key Dates

Keywords

Tarsus Pharmaceuticals, Seshadri Neervannan, Form 4, Share Sale, Tax Withholding, Restricted Stock Units, Officer Transaction